|
[1] GHANY MG, STRADER DB, THOMAS DL, et al.Diagnosis, management, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.
|
|
[2]SHEPARD CW, FINELLI L, ALTER MJ.Global epidemiology of hepatitis C virus infection[J].Lancet Infect Dis, 2005, 5 (9) :558-567.
|
|
[3]MOSLEY J, OPERSKALSKI E, TOBLER L, et al.Viral and host factors in early hepatitis C virus infection[J].Hepatology, 2005, 42 (1) :86-92.
|
|
[4]BERTOLETTI A, FERRARI C.Kinetics of the immune response during HBV and HCV infection[J].Hepatology, 2003, 38 (1) :4-13.
|
|
[5]DETERDNG K, WIEGAND J, GRUNER N, et al.The German Hep-Net acute hepatitis C cohort:impact of viral and host factors on the initial presentation of acute hepatitis C virus infection[J].Z Gastroenterol, 2009, 47 (6) :531-540.
|
|
[6]ORLAND J, WRIGHT T, COOPER S.Acute hepatitis C[J].Hepatology, 2001, 33 (2) :321-327.
|
|
[7]LOOMBA R, RIVERA M, MCBURNEY R, et al.The natural history of acute hepatitis C:clinical presentation, laboratory findings and treatment outcomes[J].Aliment Pharmacol Ther, 2011, 33 (5) :559-565.
|
|
[8]SANTANTONIO T, WIEGAND J, GERLACH JT.Acute hepatitis C:current status and remaining challenges[J].J Hepatol, 2008, 49 (4) :625-633.
|
|
[9]RAO H, SUN D, JIANG D, et al.IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection[J].J Viral Hepat, 2012, 19 (3) :173-181.
|
|
[10]RERKSUPPAPHOL S, HARDIKAR W, DORE G.Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children[J].J Gastroenterol Hepatol, 2004, 19 (12) :1357-1362.
|
|
[11]MICALLEF J, KALDOR J, DORE G.Spontaneous viral clearance following acute hepatitis C infection:a systematic review of longitudinal studies[J].J Viral Hepat, 2006, 13 (1) :34-41.
|
|
[12]GERLACH JT, DIEPOLDER HM, ZACHOVAL R, et al.Acute hepatitis C:high rate of both spontaneous and treatment-induced viral clearance[J].Gastroenterology, 2003, 125 (1) :80-88.
|
|
[13]WANG C, KRANTZ E, KLARQUIST J, et al.Acute hepatitis C in a contemporary US cohort:modes of acquisition and factors influencing viral clearance[J].J Infect Dis, 2007, 196 (10) :1474-1482.
|
|
[14]LEHMANN M, MEYER MF, MONAZAHIAN M, et al.High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection[J].J Med Virol, 2004, 73 (6) :387-391.
|
|
[15]REHERMANN B.Hepatitis C virus versus innate and adaptive immune responses:a tale of coevolution and coexistence[J].J Clin Inves, 2009, 119 (7) :1745-1754.
|
|
[16]STEGMANN KA, BJORKSTROM NK, CIESEK S, et al.Interferon alpha-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1[J].J Infect Dis, 2012, 205 (9) :1351-1362.
|
|
[17]POST J, RATNARAJAH S, LLOYD AR.Immunological determinants of the outcomes from primary hepatitis C infection[J].Cell Mol Life Sci, 2009, 66 (5) :733-756.
|
|
[18]SCHLAPHOFF V, LUNEMANN S, SUNEETHA PV, et al.Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD81 T cells[J].PLoS Pathog, 2011, 7 (5) :e1002045.
|
|
[19] GE D, FELLAY J, THOMPSON A, et al.Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance[J].Nature, 2009, 461 (7262) :399-401.
|
|
[20]BEINHARDT S, ABERLE JH, STRSEEER M, et al.Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection[J].Gastroenterology, 2012, 142 (1) :78-85.
|
|
[21] THOMAS D, THIO C, MARTIN M, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.
|
|
[22]COX A, NETSKI D, MOSBRUGER T, et al.Prospective evaluation of community-acquired acute-phase hepatitis C virus infection[J].Clin Infect Dis, 2005, 40 (7) :951-958.
|
|
[23]MCGOERRN BH, BRICH CE, BOWEN MJ, et al.Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria[J].Clin Infect Dis, 2009, 49 (7) :1051-1060.
|
|
[24]TRBUSEK J.Contribution of HCV core antigen testing in HCV diagnosis by test from the company Abbott laboratories[J].Epidemiol Mikrobiol Imunol, 2009, 58 (4) :207-208.
|
|
[25]PETERSON J, GREEN G, IIDA K, et al.Detection of hepatitis C core antigen in the antibody negative“window”phase of hepatitis C infection[J].Vox Sang, 2000, 78 (2) :80-85.
|
|
[26]GU S, LIU J, ZHANG H, et al.Core antigen tests for hepatitis C virus:a meta-analysis[J].Mol Biol Rep, 2012, 39 (8) :8197-8208.
|
|
[27]WIEGAND J, BUGGISCH P, BOECHER W, et al.Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection:the HEP-NET acute-HCV-II study[J].Hepatology, 2006, 43 (2) :250-256.
|
|
[28]KAMAL SM, FOULY AE, KAMEL RR, et al.Peginterferon alfa-2b therapy in acute hepatitis C:impact of onset of therapy on sustained virologic response[J].Gastroenterology, 2006, 130 (3) :632-638.
|
|
[29] European Association for the Study of the Liver.EASL clinical practice guidelines:management of hepatitis C virus infection[J].J Hepatol, 2011, 55 (2) :245-264.
|
|
[30]DETERDING K, GRUNER NH, BUGGISCH P, et al.Delayed versus immediate treatment for patients with acute hepatitis C:a randomised controlled non-inferiority trial[J].Lancet Infect Dis, 2013, 13 (6) :497-506.
|
|
[31]DEUFFIC-BURBAN S, CASTEL H, WIEGAND J, et al.Immediate versus delayed treatmentin patients with acute hepatitis C based on IL28B polymorphism:a modelbased analysis[J].J Hepatol, 2012, 57 (2) :260-266.
|
|
[32]CALLERI G, CARITI G, GAIOTTINO F, et al.A short course of pegylated interferon-alpha in acute HCV hepatitis[J].J Viral Hepat, 2007, 14 (2) :116-121.
|
|
[33]KAMAL SM, MOUSTAFA KN, CHEN J, et al.Duration of peginterferon therapy in acute hepatitis C:a randomized trial[J].Hepatology, 2006, 43 (5) :923-931.
|
|
[34] European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of hepatitis C virus infection[J].J Hepatol, 2014, 60 (2) :392-420.
|
DownLoad: